Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Bupropion Hydrochloride Extended-Release Tablets, USP (SR), a therapeutically equivalent generic version of Zyban® (Bupropion Hydrochloride) Extended-Release Tablets, approved by the U.S. Food and Drug Administration (USFDA).
The Zyban® brand and generic had U.S. sales of approximately $5.4 million MAT for the most recent twelve months ending in June 2019 according to IQVIA Health*.
Dr. Reddy's Bupropion Hydrochloride Extended-Release Tablets, USP (SR) are available as 150 mg dosage strength in bottle count sizes of 60.
Zyban® is a-trademark of GSK group of companies.
Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.2601.7 as compared to the previous close of Rs. 2531.9. The total number of shares traded during the day was 39253 in over 1983 trades.
The stock hit an intraday high of Rs. 2608.45 and intraday low of 2531. The net turnover during the day was Rs. 101351487.